Male breast carcinoma: A clinicopathological and immunohistochemical characterization study

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 10, 2014, Pages 6852-6861

  Zhou, Ruoji ^a,b   Yu, Lin ^a,b   Zhou, Shuling ^a,b   Bi, Rui ^a,b   Shui, Ruohong ^a,b   Yu, Baohua ^a,b   Lu, Hongfen ^a,b   Cai, Xu ^a,b   Yang, Wentao ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Breast carcinoma; Immunohistochemistry; Male; Molecular subtype

Indexed keywords

ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; CARRIER PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; GLYCOPROTEIN; PIP PROTEIN, HUMAN; REPRESSOR PROTEIN; SECRETOGLOBIN; TUMOR MARKER;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST TUMOR; CARCINOMA; CHEMISTRY; CHINA; EPIDEMIOLOGY; ETHNOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; TUMOR INVASION;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS, MALE; CARCINOMA; CARRIER PROTEINS; CHINA; FORKHEAD TRANSCRIPTION FACTORS; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; SECRETOGLOBINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84912105837     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2010; 28: 232-39.
3. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010; 28: 2114-22.
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumors. Nature 2000; 406: 747-52.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
6. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50.
7. Sanchez-Munoz A, Roman-Jobacho A, Perez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, Sáez MI, de Luque V, Medina L, Ramírez-Tortosa CL, Vicioso L, Medina JA, Ribelles N, Alba E. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. Oncology-Basel 2012; 83: 228-33.
8. Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, Dent J, Fulford L, Honarpisheh H, Jordan L, Jones JL, Kanthan R, Maraqa L, Litwiniuk M, Mottolese M, Pollock S, Provenzano E, Quinlan PR, Reall G, Shousha S, Stephens M, Verghese ET, Walker RA, Hanby AM, Speirs V. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 2012; 133: 949-58.
9. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 2012; 25: 398-404.
10. Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, Guo M. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 2009; 11: R28.
11. Liu T, Tong Z, He L, Zhang L. Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases. Breast Care (Basel) 2011; 6: 446-51.
12. Xia LP, Zhou FF, Guo GF, Wang F, Wang X, Yuan ZY, Zhang B. Chinese female breast cancer patients show a better overall survival than their male counterparts. Chin Med J (Engl) 2010; 123: 2347-52.
13. Mazoujian G, Bodian C, Haagensen DJ, Haagensen CD. Expression of GCDFP-15 in breast carcinomas. Relationship to pathologic and clinical factors. Cancer 1989; 63: 2156-61.
14. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs. GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007; 127: 103-13.
15. Fritzsche FR, Thomas A, Winzer KJ, Beyer B, Dankof A, Bellach J, Dahl E, Dietel M, Kristiansen G. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol 2007; 22: 1221-30.
16. Lewis GH, Subhawong AP, Nassar H, Vang R, Illei PB, Park BH, Argani P. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol 2011; 135: 587-91.
17. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23: 205-12.
18. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 2010; 124: 607-17.
19. Fox SB, Brown P, Han C, Ashe S, Leek RD, Harris AL, Banham AH. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 2004; 10: 3521-27.
20. Kidwai N, Gong Y, Sun X, Deshpande CG, Yeldandi AV, Rao MS, Badve S. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res 2004; 6: R18-23.
21. Murphy CE, Carder PJ, Lansdown MR, Speirs V. Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol 2006; 32: 44-47.
22. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-74.
23. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast. 4th edition. Lyon: IARC; 2012.
24. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
25. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47.
26. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95.
27. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
28. Li D, Xiao X, Yang W, Shui R, Tu X, Lu H, Shi D. Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. Mod Pathol 2012; 25: 567-75.
29. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004; 101: 51-57.
30. Burga AM, Fadare O, Lininger RA, Tavassoli FA. Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch 2006; 449: 507-12.
31. Nassar H, Wallis T, Andea A, Dey J, Adsay V, Visscher D. Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod Pathol 2001; 14: 836-41.
32. Anderson WF, Devesa SS. In situ male breast carcinoma in the surveillance, epidemiology, and end results database of the National Cancer Institute. Cancer 2005; 104: 1733-41.
33. Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast - A morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma - A preliminary report. Cancer 1998; 83: 2139-49.
34. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, Donohue JH. Molecular markers in male breast carcinoma. Cancer 1998; 83: 1947-55.
35. Curigliano G, Colleoni M, Renne G, Mazzarol G, Gennari R, Peruzzotti G, de Braud E, Robertson C, Maiorano E, Veronesi P, Nolè F, Mandalà M, Ferretti G, Viale G, Goldhirsch A. Recognizing features that are dissimilar in male and female breast cancer: expression of p21(Waf1) and p27(Kip1) using an immunohistochemical assay. Ann Oncol 2002; 13: 895-902.
36. Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001; 182: 389-92.
37. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 2007; 20: 208-14.
38. Koon HB, Ippolito GC, Banham AH, Tucker PW. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets 2007; 11: 955-65.